Study summary
Tirzepatide lowered heart failure events in people with obesity and HFpEF
9.9%had cardiovascular death or worsening heart failure, vs 15.3% with placebo
What was tested
Weekly tirzepatide against placebo in heart failure with preserved ejection fraction (50% or more) and obesity.
What they found
- Cardiovascular death or worsening heart failure: 9.9% vs 15.3%.
- Quality-of-life score improved 19.5 vs 12.7 points.
- Stomach side effects led 6.3% to stop.
What it means
Weight-loss drugs are now part of treating obesity-related HFpEF.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.